The litigation, Basma v. GeneDx Holdings Corp., follows a sharp decline in the company's valuation after it revealed disappointing financial results on May 4, 2026. GeneDx reported a drop in adjusted gross margins to 69% and missed revenue targets for its exome and genome product lines. The company subsequently slashed its full-year revenue guidance to a range of $475 million to $490 million, down from its previous forecast of up to $550 million.

Legal representatives from Kahn Swick & Foti, LLC allege that the company failed to communicate critical data during the class period. Investors were also blindsided by a $31.2 million impairment loss tied to the acquisition of Fabric Genomics, a firm GeneDx had previously marketed as a key driver for future recurring revenue. Following these disclosures, the company's share price plummeted by $33.42, representing a 49.2% loss in value. Affected shareholders seeking legal counsel or further information regarding the filing process are directed to the ClaimsFiler portal.